| Autor: |
Moreno‐Arrones, O.M., Lobato‐Berezo, A., Gomez‐Zubiaur, A., Arias‐Santiago, S., Saceda‐Corralo, D., Bernardez‐Guerra, C., Grimalt, R., Fernandez‐Crehuet, P., Ferrando, J., Gil, R., Hermosa‐Gelbard, A., Rodrigues‐Barata, R., Fernandez‐Nieto, D., Merlos‐Navarro, S., Vañó‐Galván, S. |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Mar2021, Vol. 35 Issue 3, pe181-e183, 3p |
| Abstrakt: |
It also should be pointed out that approximately 1 in 10 patients suffered ATE with a subclinical SARS-CoV-2 infection, and therefore, in the context of the pandemic, past SARS-CoV-2 infection should be considered in every patient consulting for ATE. Collected data from these patients suggest that a symptomatic SARS-CoV-2 infection is a risk factor for the development of ATE and physicians could warn patients of this possible outcome. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been recently linked to dermatologic manifestations1 and is thought to affect more severely patients with androgenetic alopecia.2 We designed a prospective multicentric study, which enrolled patients from March to August 2020 with acute telogen effluvium (ATE) that had a prior SARS-CoV-2 infection confirmed either by serological tests [e.g. detection of serum antibodies against the virus via enzyme-linked immunosorbent assays (ELISAs)] or by detection of viral RNA using real-time reverse transcription polymerase chain reaction (RT-PCR). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text